Table 1.
Patient characteristics of the cohort
| Characteristics | EBV‐neg (n = 403) | EBV‐pos (n = 30) | P Value |
|---|---|---|---|
| Sex(M) | 177 (54%) | 15 (65%) | NS |
| Age | 61 (18‐89.95) | 66.7 (38.5‐90) | 0.018 |
| Age > 60 | 215 (58%) | 21 (72%) | NS |
| Stage > 2 | 211 (58%) | 18 (75%) | NS |
| ECOG > 1 | 69 (24%) | 9 (38%) | NS |
| LDH > N | 179 (59%) | 12 (48%) | NS |
| EN > 1 | 90 (31%) | 8 (35%) | NS |
| IPI (n = 371) | |||
| 0 | 38 (11%) | 1 (4%) | NS |
| 1,2 | 156 (45%) | 11 (41%) | |
| 3,4,5 | 150 (44%) | 15 (55%) | |
| COO (L2Cx) (n = 307) | |||
| GCB | 174 (61%) | 16 (69%) | NS |
| ABC | 75 (26%) | 2 (9%) | |
| UC | 35 (13%) | 5 (22%) | |
| Therapy | |||
| R‐CHOP | 335 (83%) | 27 (90%) | |
| Other therapy (with outcome) | 19 (5%) | 3 (10%) | |
| Other (no outcome/trial therapy etc) | 49 (12%) | ||